Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
RGEN Stock Chart & Stats
$166.52
$0.11(0.07%)
At close: 4:00 PM EST
$166.52
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$102.97 - $182.52
Previous CloseN/A
Volume111.19K
Average Volume (3M)932.75K
Market Cap
$9.29B
Enterprise Value$7.50B
Total Cash (Recent Filing)$748.75M
Total Debt (Recent Filing)$688.87M
Price to Earnings (P/E)6421.0
Beta0.99
Next Earnings
Feb 25, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding56,290,750
10 Day Avg. Volume647,636
30 Day Avg. Volume932,749
Financial Highlights & Ratios
PEG Ratio1.84
Price to Book (P/B)4.08
Price to Sales (P/S)12.69
P/FCF Ratio56.51
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue10.59
Enterprise Value/Gross Profit23.34
Enterprise Value/Ebitda56.05
Forecast
1Y Price Target
$181.20Price Target Upside8.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)1.67
Revenue Forecast (FY)$732.93M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRepligen shares have rebounded strongly this year, fueled by revenue growth year-round and improved earnings in the first half of 2025, as well as by general optimism for the bioprocessing sector as a whole.
Revenue GrowthRepligen reported solid operational results, delivering outperformance from both a revenue and earnings perspective, with revenue growing high-teens organically driven by double-digit growth across all franchises and regions.
Strategic PartnershipsRepligen established a strategic partnership with Novasign to integrate digital twin capabilities into its filtration systems, enhancing digitalization and strengthening its portfolio of process analytical technology-enabled systems.
Bears Say
Biotech Funding CycleAn elongated biotech funding cycle might create direct constraints on customer demand and equipment investments.
Earnings Growth ChallengesHigher fixed costs and higher contributions from recent acquisitions and new products may dampen earnings growth in the near future despite expected revenue growth.
Margins And ExpensesEBIT margins narrowed to the lower end of prior guidance due to $2M in one-time operating expenses and some foreign exchange pressures.
Repligen News
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $102.97 and its highest was $182.52 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $9.29B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Feb 25, 2026 which is in 82 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Oct 28, 2025. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.422 by $0.038.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.44.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,290,750 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.46 in its last earnings report, beating expectations of $0.422. Following the earnings report the stock price went down -5.916%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$181.20 (8.82% Upside)
$181.20 (8.82% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 483.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.13%
12-Months-Change
Fundamentals
Return on Equity
0.08%
Trailing 12-Months
Asset Growth
3.29%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
RGEN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant organic growth, record order growth, and improved financial guidance. However, challenges remain, particularly with the China market and gene therapy headwinds. Despite these challenges, the company is optimistic about its strategic investments and future growth opportunities.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$181.20
▲(8.82% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.62% Insiders
35.64% Mutual Funds
15.74% Other Institutional Investors
27.42% Public Companies and
Individual Investors